Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and…
Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung…
New leader to drive the digital transformation Novartis has embarked upon BASEL, 28-Aug-2017 — /EuropaWire/ — Novartis announced today that Bertrand…
Total investment of EUR 105 million in Prevalje site reinforces commitment to largest Sandoz business, Anti-Infectives, and single largest global…
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce…
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since…
Alcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device…
Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study…
Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong…
EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have…
OXFORD, 17-12-2015 — /EuropaWire/ — Helena Bragd tillsätts som vd för Becton, Dickinson and Companys (BD) affärsenhet BD Nordics. Helena…
OXFORD, 17-12-2015 — /EuropaWire/ — Helena Bragd has joined global medical technology leader Becton, Dickinson and Company (BD) as General…
Ultibro® Breezhaler® met primary endpoint and demonstrated superiority to Seretide® in reducing COPD exacerbations during 52 weeks of treatment First…
Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar…
In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for…
Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments…
Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced…
Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy,…
Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped…
New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria…
Promacta® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this…
Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms…
Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results…
QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM…
New analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS…
Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea…
Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8…
With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have…
Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and…
Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels[1] Signifor LAR, a…
Acromegaly is a rare pituitary disorder, which requires normalization of hormonal levels to help prevent the serious consequences of the…
CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on…
Secukinumab met primary and key secondary endpoints in two pivotal Phase III studies showing superiority to placebo in patients with…
KAE609 is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over…
Novartis acquires exclusive ex-US rights to Fovista from Ophthotech; upfront payment of USD 200 million plus potential future recruitment and…
Company is pleased to host second international conference dedicated to the research of rare and orphan diseases Novartis is engaging…
Novartis announces that researchers can now request access to patient level data on newly approved innovative medicines in the United…
FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is…
Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials Bexsero, already…
In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional…